Phase II trial of KTN 3379 as part of combination therapy in patients with cancer.
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2016
At a glance
- Drugs CDX-3379 (Primary) ; Antineoplastics
- Indications Cancer
- Focus Therapeutic Use
- Sponsors Kolltan Pharmaceuticals
- 08 Jan 2016 Planned initiation date changed from 1 Jun 2015 to 1 Jan 2016, as per Kolltan Pharmaceuticals media release.
- 07 Nov 2014 New trial record